Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 288

Results For "MIT"

5141 News Found

USFDA inspects contract manufacturing facility of Jubilant Pharmova at Montreal Canada
Drug Approval | June 01, 2023

USFDA inspects contract manufacturing facility of Jubilant Pharmova at Montreal Canada

The US FDA in its communication mentioned it may withhold approval of any pending applications or supplements in which this facility is listed.


Lupin receives USFDA approval from Obeticholic Acid Tablets
Drug Approval | June 01, 2023

Lupin receives USFDA approval from Obeticholic Acid Tablets

Obeticholic Acid Tablets had estimated annual sales of US$ 262 million in the U.S. (IQVIA MAT Mar 2023).


Glenmark sets GHG emission targets for FY2035
Sustainability | June 01, 2023

Glenmark sets GHG emission targets for FY2035

The target boundary includes biogenic land?related emissions and removals from bioenergy feedstock


HMD supplied 1.75 billion syringes of the total 13.3 billion COVID 19 vaccines administered globally
News | June 01, 2023

HMD supplied 1.75 billion syringes of the total 13.3 billion COVID 19 vaccines administered globally

HMD had supplied 921.7 million syringes to the Government of India to facilitate over 2.2 billion Vaccination in India till date


Synexa Joins CEPI in advancing global epidemic preparedness and response
News | May 31, 2023

Synexa Joins CEPI in advancing global epidemic preparedness and response

Synexa joins CEPI’s esteemed Central Lab Network to improve global epidemic preparedness


Janssen Tremfya excels as psoriasis treatment, outshining IL-17s, says GlobalData
News | May 31, 2023

Janssen Tremfya excels as psoriasis treatment, outshining IL-17s, says GlobalData

The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab


Concept Medical gets 4th IDE approval from USFDA
Drug Approval | May 31, 2023

Concept Medical gets 4th IDE approval from USFDA

For the treatment of Superficial Femoral Artery


Ind-Swift Laboratories reports FY23 PAT at Rs. 42.47 Cr
News | May 30, 2023

Ind-Swift Laboratories reports FY23 PAT at Rs. 42.47 Cr

The company reported lifetime high EBIDTA of Rs. 250 crores


Hikal posts FY23 PAT at Rs. 36 Cr
News | May 30, 2023

Hikal posts FY23 PAT at Rs. 36 Cr

Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22


Jubilant Pharmova posts Q4FY23 consolidated loss at Rs. 97.84 Cr
News | May 30, 2023

Jubilant Pharmova posts Q4FY23 consolidated loss at Rs. 97.84 Cr

The company has reported total income of Rs. 1682.45 crores during the period ended March 31, 2023